@article {Chong2020.04.12.20063016, author = {Weelic Chong and Yang Hai and Jian Zhou and Lun-xu Liu}, title = {Pathologic Nodal Upstaging Predictive Models for CT-based Clinical Node Negative Non-Small Cell Lung Cancer}, elocation-id = {2020.04.12.20063016}, year = {2020}, doi = {10.1101/2020.04.12.20063016}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Accurate clinical nodal staging of non-small cell lung cancer (NSCLC) is essential for surgical management. Some clinical node negative cases diagnosed preoperatively by CT were later staged as pathological N1 (pN1) or pN2. Our study aimed to evaluate factors related to pathological nodal upstaging and develop statistical models for predicting upstaging.Methods We retrospectively reviewed 1,735 patients with clinical node negative NSCLC from 2011 to 2016 in the West China Lung Cancer database. Demographic and clinical data were analyzed via univariate and multivariate approaches. Predictive models were developed on a training set and validated with independent datasets.Results 171 (9.9\%) clinical node negative patients have pathologic nodal upstaging to pN1. 191(11.0\%) patients were upstaged to p(N1+N2). 91(5.2\%) patients have pSN2 pathologic nodal upstaging. Preoperative factors were used to establish 3 statistical models for predicting pathological nodal upstaging. The area under the receiver operator characteristic (AUC) were 0.815, 0.768, and 0.726, for pN1, p(N1+N2) and pSN2 respectively.Conclusion Our models may help evaluate the possibility of nodal upstaging for clinical node negative NSCLC and enable surgeons to form appropriate plans preoperatively. External validation in a prospective multi-site study is needed before adoption into clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was directly used for this study. LL was supported by Key Science and Technology Program of Sichuan Province, China (2016FZ0118). WC is supported by the Dubbs MDPHD scholarship award from Thomas Jefferson University. Publication is made possible in part by support from the Thomas Jefferson University + Philadelphia University Open Access Fund.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and data analysis tools are included in the submission.NSCLCnon-small cell lung cancerpNpathological node stagecNclinical node stageCTcomputed tomographyPET-CTpositron emission tomography-computed tomographyVATSvideo-assisted thoracic surgeryFSfrozen specimenAUCarea under the curveRULright upper lobeRMLright middle lobeRLLright lower lobeLULleft upper lobeLLLleft lower lobeGGOground-glass opacityORodds ratioCIconfidence intervalEBUS-TBNAendobronchial ultrasound-transbronchial needle aspirationEUB-FNAendoscopic ultrasound-fine needle aspiration}, URL = {https://www.medrxiv.org/content/early/2020/04/17/2020.04.12.20063016}, eprint = {https://www.medrxiv.org/content/early/2020/04/17/2020.04.12.20063016.full.pdf}, journal = {medRxiv} }